until now， the ADC drugs was not proved by NIPA， and i think uh need more work to do。

but i was veryencouraged by the ADC jrugs ununl know there is a clinical child about TDXT for the her mutititions was performed in my department。

so i found that mut t the TDXT shoes uh。

very good response， and the toxicity isis嗯is small。

so i think for this kinds of patients， the TDXD is a good choice for patients with her to mutation。

and。

even compare withchemosarity plus with。

or other or or her two tickets， the the response is so good。

and i think ADC，drugs will be very嗯popular used in the future in china。

and but uh， i can know， there are many kinds of ADC jacgs with a target with a different。

different，just。

as i know， i say that uh chok to the her two， her three IH sometimes confirmed confums with this kind of different ADC jacts， especially for responconcm a aln cancer， uh， which will be the good choice for them。

and uh， um another question is about the ADC plus with umuiserapy。

as we know that for this kind of combination ADC plus with this formis is rerein rate patience。

so i think response rate is very good。

so i think maybe it's another choice in the future for loncancer patients。

but the clinical al is is proforing now。

thank i uh another。

uh， we will waiting for the result。

is this kind of clinical choals。

that's my opinion。

thank you。

in clinical work， maybe uh， i prefer red to do uh t ssue bioposy to find uh。

if the。

have to have three mumutiation。

we we we have some choance to do uh to do have to ADC drug her three ADC drug。

ifalso we can嗯find some fashient with with each ermetiication each FRADC um drug is is going going。

experiexperience going going。

so you have many choices。

uh， of course， uh btle dec d is also a kind of a choice um so the first step um we always do the an opposite find。

uh h and ggm sixction to find uh by marker。

now that's my um first step the second um， of course， we sure do。

standard treatment for the the patient， the first nine， six， nine std nine， uh， according to the uga line um。

um cccgandanine or ansisting gandine。

um if there is a recommendation， we is should do as that a second step in my clean ork， a third step um。

cording to the。

哦，肯定try哦嗯，for example， the。

chopping now zero one， another five， uh destiny， another one， uh her or another one。

uh。

we have many IDCA choice in future work。

and we maybe do more work on the combination of ADC。

treatment uh， for example， uh ADC joke combined with a commership combined with uh TI or combined with emilous surpy。

um so that's the future work we have to do and give us more um uh。

confidence to using the continue continue work。

尼马平尼。

because we see some a adverevents uh ILD in ADC。

take a trial。

so II don't think we can use ADC drug combined with the radio syerapy， especially in in cancera long nation。

so the combination would have some um。

choice。

and we do more work to give us the guttance into work。

i think in summary， it goes back to what i was just speaking to that。

we ve made a lot progress in h non small， selon cancer over the last decade， um with primarily with a therapy with target ted erapy。

this is made a big difference for patients。

but but despite that progress， there's still a lot of work to be done。

and i think that the emerging field of anybody， your concongegetes nonsmall small lon cancer is very exciting。

in the united states， we do have an approval for um trust。

imap drugs， c can uh HA signon small salon cancer patients。

so that's very exciting。

that's the first ADC approved is non small thlem cancer and the data shred that that's more twenty twenty three， which is a tropy llong cancer。

i think， is also very excting data intentiproviprovia path forcaner to an ADC for a patients with non common ous， non small sallug cancer， which is the most common form of non small salon cancaner。

er， i like the commment and say that there is a lot of emerging data， the combining data DXT with a mintherapy and and even chem motherapy safe with nda a into m， but theis， a commcommto study looking acsea tute map go AT can， which is a trope。

two agent in combation with pamallim map， theis troropid DPS the troropian mango four study， um that look that dato DXT plus pmboralasm map or the commue map plus remded。

cheam of therapy。

and all those studies have suggesties are。

potentially safe are an efficcaous approaches。

i'm globally leading whacalcalled ttroy on ong seven study， which is a come。

it's a three arm study and patients with less than fifty percent pedia， one comparing chemotherery minan therapiis， our standard of cto data DXT plus pamalalism map and a atdebasc pmas data DXT plus pamalalism map。

and there's a companion study for great in fifty percent， pedia one patient trandeizing patients to get pmballim MPSA data DXT plus pamallism map。

so。

moving these agents in the from line setting know ultimately， as we said， we're aiming for cure or a long ways from there。

it's a step wise process。

so i think the coming months years are can be very exciting。

i hope we have the opportunity to have a similar discussion in the future when we have more data。

yeah， ah think everybody uh for the contributions saving。

this was a great discussion。